

Number 2
in a series

Gastric ulcer

reduce acid...improve healing



(Artist's impression of H₂ receptor antagonist acting on receptor site in the parietal cell in gastric mucosa.)

Healing

'Tagamet', by its unique action in selectively reducing gastric acid secretion, achieves remarkable results in the treatment of gastric ulcer.¹⁻⁶ In clinical trials, 79% of 'Tagamet'-treated patients have shown complete healing in 4-6 weeks compared with only 45% in the placebo group.⁶ In addition, in a comparative controlled trial with carbenoxolone,⁵ preliminary results have shown that 'Tagamet' produced healing in 73% of patients (11/15) compared with 50% in the carbenoxolone group (8/16).

Symptomatic Relief

In gastric ulcer, overall experience has shown that more rapid and greater relief of pain is experienced in those patients receiving 'Tagamet'.⁶ However, symptomatic relief, whilst very good, is not as predictable in onset as it is in duodenal ulcer.^{3,4} For patients who experience pain during the early stages of treatment, antacids should be made available.

Tagamet

 reduces gastric acid secretion

References

1. Healing of gastric ulcer during treatment with cimetidine. (1976) *Lancet*, i, 337.
2. Treatment of gastric ulcer by cimetidine. (1977) Proceedings of the Second International Symposium on Histamine H₂-Receptor Antagonists. *Excerpta Medica*, p. 287.

3. A controlled trial of cimetidine in the treatment of gastric ulcer. (1977) Proceedings of the Second International Symposium on Histamine H₂-Receptor Antagonists. *Excerpta Medica*, p. 283.
4. Cimetidine in patients with gastric ulcer: a multicentre controlled trial. (1977) *Brit. med. J.*, 2, 795.
5. Double-blind trial comparing

cimetidine with carbenoxolone in the treatment of benign gastric ulcer. (1977) *Gut*, 18, A420.

6. Data on file. Smith Kline & French.

'Tagamet' (cimetidine) is available as 200mg film-coated tablets, 200mg/5ml syrup and 200mg/2ml ampoules.

'Tagamet' is a trade mark.

Full prescribing information is available from:-


SK&F
a SmithKline company

Smith Kline & French Laboratories Limited
Welwyn Garden City
Hertfordshire AL7 1EY
Telephone: Welwyn Garden 25111 TG:AD28

New from
SQUIBB SURGICARE LIMITED

Colostomy Pack

incorporating
the **New** Colostomy Pouch Mk.1
with Stomahesive and Flange



+ Special Sealing Ring

The Squibb Surgicare Colostomy Pack:
a new, easy-to-use system of colostomy management
ensuring freedom from skin problems with extra
security comfort and convenience

From the inventors of Stomahesive™


Further information is available on request from
SQUIBB SURGICARE LIMITED
Regal House Twickenham TW13QT

Stomahesive is the registered trade mark of E. R. Squibb and Sons Limited

Vivonex Standard

for maintaining nutritional balance in patients at risk


Amino acids 8.2%, glucose solids 86.3%,
essential fat, vitamins and minerals; powder.
1.26 MJ/80 g



Vivonex HN

for restoring nitrogen balance in catabolic patients

Amino acids 17.7%, glucose solids 79.1%,
essential fat, vitamins and minerals; powder.
1.26 MJ/80 g



'Vivonex' is a registered trade mark.

PL 0364/0017 PA 170/4/1
PL 0364/0014 PA 170/3/1

Further information is available from



Eaton Laboratories
Regent House, The Broadway,
Woking, Surrey GU21 5AP

Nature nearly discovered a cure for duodenal and gastric ulcers.



ASTRAGALUS
GLYCYPHYLLOS

We just perfected it.

For thousands of years, liquorice has been used medicinally. For the past thirty years, its efficacy in promoting the natural healing of gastric and duodenal ulcers has been acknowledged.

Now CAVED*-S offers the full therapeutic benefits of liquorice without the disadvantages which formerly limited its use. An exclusive process removes the glycyrrhizinic acid responsible for salt and water retention, without diminishing the efficacy of medicinal liquorice in accelerating ulcer healing.

With its proven record of reliability and lack of side effects, it makes sense to try CAVED*-S first when treating even the most severe ulcer cases.

CAVED*-S

It's naturally the treatment of choice.

Detailed information is available on request. *trademark.

Tillotts Laboratories Unit 24, Henlow Trading Estate,
Henlow, Beds. Telephone: 0462 813933



DOROTHY'S REFINED HABITS HAVE LED TO A SERIOUS PROBLEM.

Many patients suffer from serious conditions such as haemorrhoids, diverticular disease, irritable colon or anal fissure, which may be associated with long standing dietary constipation.

These problems won't be resolved overnight. Fybogel, by quickly restoring natural fibre to the diet, relieves the constipation and rapidly improves the symptoms of the condition.



Fybogel sachets contain 3.5 g Ispaghula husk BPC.
Full prescribing information is available on request from
Reckitt & Colman Pharmaceutical Division, Hull HU8 7DS.
Fybogel is a registered trademark. PL No. 0044/0041. 1127




the natural way to end dietary constipation


Ulcer heal thyself!




Day 1 The liquid De-Nol flows into the empty stomach and duodenum and comes into direct contact with the ulcer. The active ingredient in De-Nol, a chelate, combines with the free amino acids and proteins at the ulcer site by secondary chelation. In this way a protective layer is formed.¹




Day 3 The protective coagulum defends the ulcer against both acid and pepsin. Early symptomatic relief is obtained and natural healing is obtained. De-Nol's therapeutic effect is localised rather than systemic. No serious side effects occur.



Day 28 A complete course of De-Nol lasts just 28 days. After this time it has been shown, endoscopically, that up to 90% of ulcers are completely healed.² A second course of De-Nol may occasionally be required, particularly in resistant cases.



Day 425 A recently published study³ showed that in 83% (15 out of 18) of gastric ulcer patients successfully treated with De-Nol there had been no relapse within fourteen months (425 days).



De-Nol

Heals ulcers by helping them heal themselves

References: 1 Lavy et al, Archives int. de Pharm. et la Therapie 224.2 1976. 2 Salmon et al, GUT 15, 189 1974. 3 Lee & Nicholson, Med. J. Aust. 1977 1.808-812. De-Nol is a registered trademark. P/L No. 0166/5024

Full prescribing information is available upon request to

Brocades Great Britain Ltd.

Brocades House, Pyrford Road, West Byfleet, Weybridge, Surrey KT14 6RA Telephone: Byfleet 45536/42291 Telex: 917301

Another Decision



The vital
step to full rehabilitation

—decide on Hollister

After stoma surgery, the patient needs all the advice and encouragement you can give — most of all, with the right choice of appliance.

The extensive Hollister range provides the widest choice of sizes to help you select the ideal bag for each patient. Integral Karaya Seals help prevent leakage and skin problems and the special laminate construction ensures freedom from odour. We use Securicor for delivery and that's why Hollister* products normally reach you within 3 days. Now available on contract in nearly every hospital which gives low cost of procedure.

Abbott understand the physical and emotional problems of coping with an ostomy. So we provide various educational and advisory services for the benefit of medical staff and stoma patients. We would like to send you full details. Telephone: Sheerness 3371 or write to Abbott Laboratories Ltd., Freepost, Queenborough, Kent, ME11 5BR — no stamp needed.

Depend on us. We want to help.




The Team That Cares

a product of
HOLLISTER

available from
ABBOTT

ABBOTT LABORATORIES LTD., QUEENBOROUGH, KENT, ME11 5BR



Why Nalcrom should change your thinking about ulcerative colitis.

Prescribing Information

PRESENTATION: Nalcrom is a presentation of sodium cromoglycate for oral use. It is presented in clear/clear hard gelatine capsules printed Fisons 101 in black. Each capsule contains 100mg sodium cromoglycate as a white powder.

USES: As an adjuvant in the treatment of ulcerative colitis, proctitis and proctocolitis.

Sodium cromoglycate is considered to exert a stabilising effect upon mast cells capable of releasing mediators, thus preventing the local inflammatory reaction in the gastrointestinal tract.

DOSAGE AND ADMINISTRATION: Dosage Adults: Two capsules four times daily.

Children: From 2-14 years; one capsule four times daily.

Nalcrom should not be used for children under two years.

Maintenance dosage To prevent relapses dosage should be maintained indefinitely at two capsules four times daily in adults and one capsule four times daily in children.


Administration The capsules may be swallowed whole or alternatively the powder contents may be dissolved in 20-30ml of water and swallowed.

Nalcrom offers a completely new approach to the management of ulcerative colitis.

And it could mean freedom from side effects often associated with the limited number of treatments now available.


Nalcrom is sodium cromoglycate.

Sodium cromoglycate is the unique drug which is used successfully in the treatment of allergic diseases, such as asthma and rhinitis.



Sodium cromoglycate prevents the degranulation of mast cells caused by the interaction of antigens and reagin antibodies.

It is a potent inhibitor of mast cell degranulation. It prevents the release of inflammatory agents into sub-mucosal tissue in the lung, nose and other organs. So it stops symptoms before they start. And over ten years of clinical use has proved it to be a very effective drug with remarkably few serious side-effects. Now it offers hope as a new treatment for ulcerative colitis.



On left mast cell undergoing gross degranulation. On right mast cell stabilised after treatment with sodium cromoglycate. Photomicrographs prepared by: R & D Laboratories, Fisons Ltd., Pharmaceutical Division.

References 1. Heatley, R.V. et al, 1975, "Gut," **16**, 559 2. Mani, V. et al, 1976, "Lancet," **1**, 439 3. Mani, V. et al, 1977, "Gastro-enterology," **72**, 1093.

Please arrange for a specialist representative to call.

Name _____

Address _____

Further information is available on request from Fisons Limited, Pharmaceutical Division, Loughborough, Leicestershire.

CONTRA-INDICATIONS, WARNINGS, ETC: **Contra-indications** There are no specific contra-indications. The safety of Nalcrom during pregnancy has not yet been established.

Side-effects Nausea has been reported in a few cases.

Overdosage As Nalcrom is absorbed only to a very limited extent, no action other than medical observation should be necessary.


PHARMACEUTICAL PRECAUTIONS: Store in a dry place. Reclose the container tightly after use.

LEGAL CATEGORY: P.O.M.

PACKAGE QUANTITIES: Containers of 100 capsules.

Why an anti-allergy drug?

Ulcerative colitis in its natural history and histological appearance has many features such as macrophages, mast cells and eosinophils that suggest that an allergic or immunological process may be involved. Sodium cromoglycate may have a clinically beneficial effect in these processes. So a double blind cross-over trial was carried out with 26 patients suffering from chronic proctitis¹. The 14 responders to sodium cromoglycate had a high local eosinophil count which in most cases fell in the course of treatment.



In a double-blind cross-over trial of 26 patients, 14 responded to sodium cromoglycate, 10 didn't respond and 2 responded to placebo

Another study of 12 patients with ulcerative colitis treated with sodium cromoglycate showed a significant improvement in sigmoidoscopic appearance. And again, rectal biopsies showed a significant reduction in eosinophil counts^{2,3}.

How to find out more about Nalcrom.

Specialist representatives are available at this stage to discuss Nalcrom with hospital doctors. Simply fill in and post the coupon or write to: Fisons Limited, Pharmaceutical Division, Loughborough, Leicestershire.

Nalcrom[®]
(Sodium Cromoglycate B.P.)

FISONS[®]
Leaders in Allergy Research

G/N/5

FURTHER INFORMATION: 1. Nalcrom may be used in conjunction with steroid therapy and sulphasalazine in the treatment of acute relapses of proctocolitis and in maintaining remissions.

2. If steroid therapy is to be reduced or withdrawn this should be done cautiously.


3. Nalcrom may be used in patients with a history of hypersensitivity to or intolerance of sulphasalazine.

4. Dosages of 2000mg daily have been used in some cases of proctocolitis.




PRODUCT LICENCE NUMBER: PL 0113/0073.

NEW ENDOSCOPY EQUIPMENT AND TEACHING MODELS

**HEMISPHERIC ENDOSCOPY
TEACHING MODEL**



ENDOSCOPY TROLLEY



SECURITY ENDOSCOPY CABINET

Please send for further details to:

Tillomed Laboratories Limited, Henlow Trading Estate, Henlow, Beds. Tel: 0462-813933

Chendol

A New Product
developed by extensive research
over many years of hard work



Some stones you'd give a lot to own—others you'd rather lose.

Chendol capsules dissolve cholesterol gallstones

CHENDOL is a new form of medication developed by Weddel Pharmaceuticals to dissolve cholesterol gallstones over a period of time.

Results of recent studies have demonstrated a 93% success rate in the U.K.¹ and 81% in the U.S.A.² for dissolving cholesterol gallstones in patients with a functioning gallbladder.

INDICATIONS For dissolution of cholesterol gallstones in functioning gallbladders. Cholesterol stones coated with calcium, or stones composed of bile pigments are not dissolved by chenodeoxycholic acid. It has a particular place in the treatment of patients in whom surgery is contraindicated or who are anxious to avoid surgery.

DOSAGE The present clinical evidence suggests that optimum results will be obtained on a dose level of 10–15 mgs. per kg body weight daily in divided doses.

CONTRAINDICATIONS, WARNINGS, ETC. CHENDOL should not be administered to patients with radio-opaque calcified gallstones nor to patients with non-functioning

CHENDOL—chenodeoxycholic acid—reduces the amount of cholesterol secreted into the bile. Lithogenic bile becomes unsaturated and precipitated cholesterol is slowly dissolved.

gallbladders. In addition, at present CHENDOL should not be administered to women of child-bearing age, nor to patients with chronic liver disease, nor with inflammatory diseases of small intestine and colon.

CHENDOL is generally well tolerated; the only side effects reported to date are diarrhoea and pruritus. It has been found that after a slight reduction in dose for a few days diarrhoea ceases and the dose can then gradually be increased to the former level. Laboratory monitoring should accompany treatment.

Each Chendol capsule contains 125 mg of chenodeoxycholic acid.

Available in securitainers of 100 capsules.—N.H.S. cost £13.50 per pack.



**Weddel
pharmaceuticals
limited**

Red Willow Road,
Wrexham Industrial Estate,
Wrexham, Clwyd, LL13 9PX.

PL 0495/0003

Reference: 1. Maton, P. N., Iser, J. H., Murphy, G. M. and Dowling, R. H. Efficacy of, withdrawal from and resistance to chenodeoxycholic acid treatment in patients with gallstones. *Gut*, 1977, 18, A976 (abstract).

2. Thistle, J. L., Hofmann, A. F., Ott, B. J. and Yu, P. Y. S. (1976). Gallstone dissolution with chenodeoxycholic acid 1969–1976: The Mayo Clinic Studies. *Gastroenterology*, 70, 943 (abstract).



The Salazopyrin was stopped

The success of Salazopyrin in returning ulcerative colitis patients to a normal life often leads them to plead for the abandonment of the therapy as it no longer appears—to them—to be required.

However in a substantial number of symptom-free, apparently healthy ulcerative colitis patients sigmoidoscopy or biopsy reveals that the disease is still present. Cessation of Salazopyrin therapy increases the likelihood of the return of the distressing malady four fold, even several years after the acute attack.²

**In ulcerative colitis
Salazopyrin —
minimum 2g per day
ad infinitum**

"We concluded that a daily dose of 1g sulphasalazine is inadequate but that a daily dose of 2g is suitable for general use as long term maintenance treatment."¹

"It is concluded that maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin) should be continued indefinitely unless contraindicated by side effects."²

Salazopyrin (sulphasalazine) is available as the plain 0.5g tablet, 0.5g EN-tab and as an 0.5g suppository.

Comprehensive literature and other detailed information on Salazopyrin are available on request.

1. Gut (1977) 18 421
2. Gut (1973) 14 923-926

Salazopyrin is a registered trade mark.

P.L. 0009/5006, 5007, 5008

Pharmacia (Great Britain) Limited,
Paramount House,
75, Uxbridge Road,
London, W.5 5SS.
Telephone: 01-579 0102/7



INTRALIPID* 10% INTRALIPID* 20%

Presentation

A milky-white oil in water emulsion. Intralipid contains fractionated soya bean oil 10% or 20% emulsified with fractionated egg lecithin at pH 7. It also contains glycerol.

Indications: Intralipid fat emulsions are indicated in conditions of severe depletion requiring also a high energy intake to compensate for excessive loss of calories following trauma, infection, fever, burns, etc.

Dosage and Administration

500-1,500ml. daily in conjunction with intravenous amino-acids are administered by slow intravenous infusion.

Infant dosage: Intralipid 10% or 20%: 15-20ml. per kg. body weight in 24 hours.

Contra-indications

Intralipid is contra-indicated in pathological hyperlipaemia and severe liver damage.

Pharmaceutical Precautions

No drugs should be added to Intralipid prior to or during infusion.

Package Quantities

Intralipid 10%: 100ml. and 500ml.
Intralipid 20%: 100ml. and 500ml.

NHS Price:

£2.75, £6.50
£3.95, £9.55

Intralipid 10% Product Licence 0022/0027
Intralipid 20% Product Licence 0022/0028

VAMIN* GLUCOSE

Presentation

Clear, straw-coloured solutions for intravenous use containing all essential amino-acids, and a balanced mixture of non-essential amino-acids in each 1,000ml. (pH 5.2). Carbohydrate, as glucose (100g/l), has been added as an energy source. Electrolytes are present, but these may need supplementing according to patient needs.

Nitrogen per litre: 9.4g. corresponding to about 60g. of first-class protein. Caloric content per litre: 650 Kcal., of which 410 Kcal. are provided by glucose.

Uses

Vamin Glucose is indicated in conditions of protein depletion where oral or intragastric feeding is impossible or impracticable.

Dosage and Administration

Depending on the individual protein requirement, 0.5-2.0 litres intravenously per day.

Infant dosage: 30-40ml. per kg. body weight in 24 hours.

Contra-indications, Warnings, etc.

Irreversible liver damage and severe uraemia when dialysis facilities are not available. Care should be taken when administering this solution to diabetic patients.

Side effects: As with all hypertonic infusion solutions, thrombophlebitis may occur when peripheral veins are used.

Package Quantities

Bottles of 100ml., 500ml. and 1,000ml.

NHS price:

£2.50, £6.75, £12.50

Product Licence 0022/0030

*Additives contain

electrolytes, trace elements,
fat soluble vitamins and
water soluble vitamins for
adults and children.

KabiVitrum 

Full prescribing information is available from
KabiVitrum Ltd., Bilton House,
Uxbridge Road, Ealing, London W5 2TH.



When you start to think about IV feeding...

.....make sure its complete and balanced, like a normal healthy diet. Intralipid and Vamin provide **all** the calories, **all** the essential fatty acids and **all** the nitrogen required for anabolism and recovery.

In addition there is now a range of additives specially tailored to meet the other nutritional requirements—vitamins, electrolytes and trace elements.

INTRALIPID VAMIN

NOW AVAILABLE—ADDITIVES*



the only nutritionally-complete recovery builders.

ACTA GASTRO-ENTEROLOGICA BELGICA

Organe de la Société belge de Gastro-entérologie

SOMMAIRE du FASCICULE 9-10

Editorial: BROHEE, D. et DELCOURT, A. (Bruxelles). La macroamylasémie.

LIGNY, G. et SMETS, Ph. (Charleroi-Bruxelles). Relation entre la concentration acide du composant pariétal de la sécrétion gastrique et le débit acide maximal chez l'homme.

COLLARD, M. et REMY, P. (Montignies-le-Tilleul). Critères diagnostiques et tomодensitométrie du pancréas.

DELCOURT, A. (Bruxelles). La pancréatite biliaire.

BROHEE, D., NAEJE, R., VAN MELSEN, A. et DELCOURT, A. (Bruxelles). La macroamylasémie.

SOMMAIRE du FASCICULE 11-12

BROECKAERT, I. et PLATTEBORSE, R. (Bruxelles). Une tumeur oesophagienne bénigne et asymptomatique constitue-t-elle une indication opératoire?

DAUBRESSE, J. C., MEUNIER, J. C. et LIGNY, G. (Charleroi). La stimulation de la sécrétion de prolactine par la cimétidine chez l'homme.

HELLER, F. et HARVENGT, C. (Louvain-en-Woluwe). La lithiase biliaire à cholestérol; physiopathologie et traitement.

SCHALM, S. W. (Rotterdam). Serum levels of chenodeoxycholic acid in health and non hepatic disease: relationship with cholelithiasis.

STALPORT, J. et RONSSE, G. (Huy). Les indications urgentes de la cholédocolithiase compliquée.

YVERGNEAUX, J. P., BAUWENS, E., VAN OUTRYVE, L. et YVERGNEAUX, E. (Gent). Etude de la papillo-infundibulotomie mesurée avec suture, à l'aide de la radiomanométrie et de la débit-métrie électronique. Etude préliminaire.

HOLLENDER, L. F., MEYER, Chr., CALDEROLI, H., DRYJSKI, J. et ALEXIU, D. (Strasbourg). Les perforations non traumatiques de l'intestin grêle en péritoine libre. Enseignement tiré d'une série de 13 cas.

DUMITRASCU, D., GRIGORESCU, M., ERDESY, St., SUCIA, A. et FODOR, O. (Cluj). Influence de l'antibiothérapie sur l'activité métabolique bactérienne dans les entéropathies.

Acta Gastro-enterologica Belgica: 6 fascicules doubles par an.

Abonnements (Belgique et Etranger): 1.500 Fr. b.


Le fascicule isolé: 250 Fr. b.

Secrétariat et rédaction: rue des Champs Elysées. 43. B 1050. Bruxelles. Belgique.

For enzymatic determination of bile acids

Sterognost-3 α

Sterognost-3 α is a highly purified and stabilized preparation of 3 α -hydroxy-steroid dehydrogenase (E.C. 1.1.1.50) from *Pseudomonas testosteroni*, presented as a ready-made enzyme kit.



Sterognost-3 α for the quantitation of bile acids in:

1. Serum
2. Bile
3. Duodenal/small intestinal aspirate
4. Fæces

Sterognost-3 α as a diagnostic tool in:

- Liver function
- Gall stone formation
- Diarrhoea - Malabsorption
- Loss of bile acids

Samples and scientific literature available from:

- Läkemedelsfabriken-Medica AB, Helsinki
 - NycoMed A/S, Copenhagen
 - Nyegaard & Co. AB, Stockholm
 - Nyegaard & Co. A/S, Oslo
- and local representatives outside Scandinavia.

Please send Sterognost-3 α

Literature ☐ Sample ☐

Name: _____

Address: _____



NYEGAARD & CO. AS

Postboks 4220 Torshov, Oslo 4.